Ways to Give
Your financial donation is the best way to ensure patients get the support they need. There are several creative ways you can give.
Myelodysplastic Syndromes (MDS)
Medical Research Basics
Learn about the process to bring new therapies and treatments to patients.
Here are explanations of why and how research is developed, the different types of research involved, and how registries are used to improve the lives of patients.
"Let's Roll:" What the Heroes of 9/11 can Teach us about Facing Blood Cancer
The morning of 9/11/01 was a doubly surreal experience for me. I was waiting for an appointment with my doctor at M. D. Anderson's Leukemia Center in Houston while chaos erupted in America. The waiting room was packed, as usual, with people at various stages of their own life-threatening events, and I was struck by the relative calm in this room compared to the state of disbelief and panic playing out on TVs throughout the country.
Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS
Approval of new agents to treat higher risk (HR) myelodysplastic syndrome (MDS) has stalled since the approval of DNA methyltransferase inhibitors (DNMTi). In addition, the options for patients with lower risk (LR) MDS who have high transfusion needs and do not harbor ring sideroblasts or 5q- syndrome are limited. Here, we review the current treatment landscape in MDS and identify areas of unmet need, such as treatment after failure of erythropoiesis-stimulating agents or DNMTis, TP53-mutated disease, and MDS with potentially targetable mutations.
Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care
Hematopoietic stem cell transplantation (HCT) is indicated for patients with higher-risk (HR) myelodysplastic syndromes myelodysplastic syndromes
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
Health-related quality of life (HRQoL) and vulnerability are variably affected in patients with myelodysplastic syndromes myelodysplastic syndrom
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes
Objectives: This study aimed to describe the burden of thrombocytopenia thrombocytopenia: (throm-buh-sie-tuh-PEE-nee-uh) A condition in which there i
Do anemia treatments improve quality of life and physical function in patients with myelodysplastic syndromes (MDS)? A systematic review
Anemia Anemia: (uh-NEE-mee-uh) A condition in which there is a shortage of red blood cells in the bloodstream. This causes a low red blood cell count.